C
Cytovale
Medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning
About Cytovale
Cytovale is a medical technology startup that operates in the healthcare sector, specifically in the field of diagnostics for fast-moving diseases. The company's primary focus is on sepsis, a potentially life-threatening condition caused by the body's response to an infection. Cytovale's flagship product, IntelliSep, is designed to provide rapid, reliable sepsis diagnosis in less than 10 minutes, a significant improvement over traditional methods that can take hours or even days.
The company's technology, known as the Cytovale system, uses host response technology to analyze thousands of cells per second. This allows it to quickly assess the state of a patient's immune system and identify disease signatures. This information can then be used by clinicians to aid in diagnosis and inform treatment decisions.
Cytovale's business model is based on selling its IntelliSep system to healthcare providers. The system offers a simple workflow with minimal hands-on time, making it an attractive option for busy healthcare settings. By providing actionable information quickly, the system can potentially improve patient outcomes and reduce healthcare costs, both of which are key selling points for potential clients.
In summary, Cytovale is a promising startup in the medical technology sector, offering a rapid, reliable solution for sepsis diagnosis. Its innovative technology and business model position it well for success in the healthcare market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- South San Francisco, United States
- Employees
- 122
- Open positions
- 2
- Dealroom signal
- 74.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Analytics, Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Applications
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Oct 2024 | $100M | $400M | CPP Investments · Global Health Investment Corporation · Breakout Ventures · Norwest Venture Partners | ↗ |
| SERIES COther financing | Nov 2023 | $84M | $336M | Sands Capital Management · Global Health Investment Corporation · Norwest Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Cytovale is 8.6K monthly website visits, up 7.5% over the last three months. Cytovale's team declined 6.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Series A4 investors entered at this stage
Dolby Family Ventures
Blackhorn Ventures
Breakout Ventures
GRIDS Capital
Series B and later5 investors entered at this stage
Western Technology Investment
Norwest Venture Partners
Sands Capital Management
Global Health Investment Corporation
CPP Investments
Other known investors2 additional known investors
Google for Startups Accelerator
University of California, Los Angeles
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cytovale on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cytovale’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







